ProfileGDS4814 / ILMN_2259730
TitleOvarian cancer xenograft tumor response to trastuzumab and pertuzumab
OrganismHomo sapiens


none trastuzumab pertuzumab trastuzumab and pertuzumab GSM780707 GSM780708 GSM780709 GSM780719 GSM780720 GSM780721 GSM780710 GSM780711 GSM780712 GSM780722 GSM780723 GSM780724 GSM780713 GSM780714 GSM780715 GSM780725 GSM780726 GSM780727 GSM780716 GSM780717 GSM780718 GSM780728 GSM780729 1% 2% 42% 33% 20% 7% 17% 6% 9% 30% 12% 8% 21% 19% 3% 6% 33% 4% 19% 7% 5% 13% 4% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM780707Untreated after 4 days (C1_1)36.99081
GSM780708Untreated after 4 days (C2_1)37.70342
GSM780709Untreated after 4 days (C3_1)48.242642
GSM780719Untreated after 4 days (C1_2)46.219133
GSM780720Untreated after 4 days (C2_2)43.477320
GSM780721Untreated after 4 days (C3_2)40.33077
GSM780710Trastuzumab treated after 4 days (T1_1)42.852817
GSM780711Trastuzumab treated after 4 days (T2_1)39.96136
GSM780712Trastuzumab treated after 4 days (T3_1)40.95349
GSM780722Trastuzumab treated after 4 days (T1_2)45.611430
GSM780723Trastuzumab treated after 4 days (T2_2)41.834412
GSM780724Trastuzumab treated after 4 days (T3_2)40.66378
GSM780713Pertuzumab treated after 4 days (P1_1)43.699221
GSM780714Pertuzumab treated after 4 days (P2_1)43.433719
GSM780715Pertuzumab treated after 4 days (P3_1)38.14363
GSM780725Pertuzumab treated after 4 days (P1_2)39.75676
GSM780726Pertuzumab treated after 4 days (P2_2)46.254833
GSM780727Pertuzumab treated after 4 days (P3_2)38.77024
GSM780716Trastuzumab and Pertuzumab treated after 4 days (TP1_1)43.39419
GSM780717Trastuzumab and Pertuzumab treated after 4 days (TP2_1)40.20167
GSM780718Trastuzumab and Pertuzumab treated after 4 days (TP3_1)39.56725
GSM780728Trastuzumab and Pertuzumab treated after 4 days (TP1_2)41.946513
GSM780729Trastuzumab and Pertuzumab treated after 4 days (TP2_2)38.9654